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The inﬂuence of FSH receptor (FSHR) variants on male infertility is not completely understood. The present investigation is the
ﬁrst screening study for SNP at nucleotide position −29 in the core promoter region and codon 680 in exon 10 of the FSHR and
the eﬀect of the serum levels of FSH on male infertility in Southeast Turkey. The SNPs in codon 680 and at position −29 of the
FSHR gene were analyzed by PCR-RFLP technique in 240 men with proven fathers, and 270 infertile men (150 nonobstructive
azoospermic and 120 severe oligozoospermic). The separate analysis for SNP at nucleotide position −29 did not show any
diﬀerence in genotypic frequencies and serum FSH levels. The genotype distribution of SNP at position 680 was diﬀerent but
does not inﬂuence serum FSH levels. Together the two SNPs form four discrete haplotypes (A-Thr-Asn, G-Thr-Asn, A-Ala-Ser,
and G-Ala-Ser) occurring in 10 combinations. A statistically signiﬁcant diﬀerence in the allelic distribution of G-Asn/G-Ser and
G-Ser/G-Ser genotype between proven fathers and infertile men but there were not any statistically signiﬁcant diﬀerence in the
overall frequency of the four FSHR haplotypes. We conclude that the FSHR haplotype does not associate with diﬀerent serum FSH
levels but it is diﬀerently distributed in proven fathers and infertile men.
1.Introduction
The interaction between follicle-stimulating hormone (FSH)
and the FSH receptor (FSHR) is essential for normal
oogenesis and spermatogenesis [1–15]. In the male, FSH
is fundamental for Sertoli cell function and the induction
and maintenance of qualitatively and quantitatively normal
spermatogenesis by a speciﬁc receptor (FSHR) that is a
member of the G protein-coupled receptor family [8, 11].
The FSHR gene spans a region of 54kb on chromosome
2p21 and consists of 10 exons and 9 introns [3, 8, 11]. The
extracellular domain is encoded by exons 1 to 9; whereas
exon 10 encodes the C-terminal part of the extracellular
domain, the complete transmembrane, and the intracellular
domain [5, 8, 11] .T h ea c t i v i t yo ft h i sg e n ei sd r i v e nb ya
core promoter spanning 225bp, which represents a TATA-
less promoter with no evident regulatory elements beside an
E-box [8, 9] and a more recently identiﬁed initiator element
(Inr) [16].
Mutation screening of the FSHR gene revealed various
single nucleotide polymorphisms (SNPs) both in the core
promoter and in the coding region [1, 8, 9, 11, 12]. A
common SNP that occurs in the core promoter at nucleotide
position −29 (−29G>A) results in a G/A exchange in a
potential GGAA binding domain for an E-26 transcription
factor, which is altered [3, 11]. The other most common SNP
in the coding region occurs at nucleotide 2039 in exon 10,
in which A/G transitions cause amino acid exchange from
asparagine to serine at codon 680 (N680S) [7, 8, 11, 12, 14].
Investigations on the distribution of these SNPs pro-
duced varying results. In the normal and infertile men and
women, some studies revealed that there is no diﬀerence in
the distribution of SNP and they have no eﬀect on serum
FSH levels [2, 7, 11, 13, 17, 18]; whereas other investigations2 Journal of Biomedicine and Biotechnology
found signiﬁcant diﬀerences between patients and controls
[6, 8, 15, 19, 20], suggesting that ethnic diﬀerences could be
involved.
This is the ﬁrst study to determine the polymorphism
of the FSHR core promoter at position −29, alone and in
combination with the SNP at codon 680 in exon 10, and to
evaluate the possible role of these two FSHR SNPs on serum
levels of FSH in Southeast Turkey.
2.MaterialsandMethods
2.1. Design. The study population consists of 240 proven
fathers (sperm count >20 × 106/mL and serum FSH
levels <7IU/L), and 270 infertile men (150 nonobstructive
azoospermic and 120 severe oligozoospermic in which
sperm count <10 × 106/mL) referred to Human Genetic
Department of Dicle University Hospital. There were not
seen karyotype abnormalities and Y chromosome long arm
microdeletions in the study population. Since “infertile”
men are a quite heterogeneous population and spermato-
genesis can vary qualitatively and quantitatively in indi-
vidual subjects, to increase the stringency of the study we
selected only men with nonobstructive azoospermia and
oligozoospermia compared them to proven fathers with
normal spermatogenesis. This study was approved by the
Hospital Ethics Committee (B.30.2.D˙ IC.0.01.00.00/80), and
writteninformedconsentwasobtainedfromallparticipants.
Genomic DNA was extracted from peripheral blood
leucocytes by standard procedures [21, 22] before being
analyzed by multiplex PCR. The SNPs at positions −29 of
promoter [11] and at nucleotide 2039 (codon 680) of exon
10 [23] were analyzed using the polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
techniquewiththeprimerswhichweredesignedbasedonthe
published sequence of the human FSHR gene. For position
−29 (rs1394205) we used forward primer: 5 -TGG TGA
ACA GCA AGG AGA CTT-3 , reverse primer: 5 -TTG GCA
GAG AAA AAC CCT GT-3 , whereas for nucleotide 2039
genotyping (codon 680) (rs6166), forward primer: 5 -CCC
AAA TTT ATA GGA CAG-3 , reverse primer: 5 -GAG GGA
CAA GTA TGT AAG TG-3. The PCR products were then
digested with the restriction enzymes (MboII for −29 and
BsrI for SNP Ser680Asn), according to the manufacturer’s
protocol. The PCR fragment following 2.5% agarose gel
electrophoresis shows three diﬀerent patterns for −29. The
uncleaved fragment, homozygous for A, has a size of 404bp;
whereas the cleaved fragment, homozygous for G, gives rise
to 289 and 115bp fragments. The Asn 680 allele gives an
undigested fragment of 520bp; whereas the Ser 680 allele
gives two fragments of 413 and 107bp. For heterozygous
(Asn/Ser), agarose gel electrophoresis allows visualization of
three bands 520bp, 413bp, and 107bp.
Semen analysis was performed according to the World
Health Organization [24]. Serum concentrations of FSH
were measured by electrochemiluminescence immunoas-
says (ECLIAs), using Roche Elecsys 1010 (Roche Diagnos-
tics, Mannheim, Germany) according to the manufacturer’s
instructions.
2.2. Data Analysis. Statistical analysis was performed
by applying a commercially available software package
(SPSS 15.0 for Windows, SPSS, Chicago, Illinois, USA). Data
were analyzed for normal distribution. Data are presented as
mean ± SEM. χ2 and one-way analysis of variance (ANOVA)
tests were used for the analysis of the data. Statistical
significance was set at P ≤ .05.
3. Results
The separate analysis for SNP at nucleotide position −29 did
not show any diﬀerence in genotypic frequencies between
proven fathers and infertile patients (χ2 = 1.182, P>. 05)
(Table 1). Similarly, SNP at nucleotide position −29 was not
associated with diﬀerent FSH concentrations in each group
(P>. 05, ANOVA) (Table 1).
WhentheSNPataminoacidpositions680wasseparately
analyzed, a statistically signiﬁcant diﬀerence was found in
the genotype frequency between three groups (χ2 = 22.87,
P<. 001). Further testing by two-by-two statistics revealed
signiﬁcant diﬀerence for genotype Asn-Ser between proven
fathers and nonobstructive azoospermic groups (χ2 = 5.26,
P<. 05), for genotype Ser-Ser between proven fathers and
nonobstructive azoospermic groups (χ2 = 6.67, P<. 05),
for genotype Asn-Ser between proven fathers and severe
oligozoospermic groups (χ2 = 5.18, P<. 05), for genotype
Asn-Ser between nonobstructive azoospermic and severe
oligozoospermic (χ2 = 15.36, P<. 001), and for genotype
Ser-Ser between nonobstructive azoospermic and severe
oligozoospermic groups (χ2 = 11.86, P<. 05). To assess
whether the polymorphism at 680 inﬂuences FSH levels,
we compared FSH concentrations among genotypes. The
FSH concentrations were not diﬀerent between the FSHR
genotypes for each group of patients and proven fathers
(P>. 05, ANOVA).
When we analyzed the haplotypes determined by the
two SNPs at position −29 and codon 680, our results
show that four possible haplotypes result from all the two
SNPs of the FSHR gene: A-Asn, G-Asn, A-Ser, and G-
Ser. These haplotypes account is combined into the 10
major combinations shown in Table 2, in which nine groups
are presented since the two possible allelic combinations
of group 5 (double heterozygous) cannot be distinguished
and are considered together. Further testing by Chi-square
revealed the signiﬁcant diﬀerence for G-Asn/G-Ser and G-
Ser/G-Ser genotype in men with proven fathers and infertile
(nonobstructive azoospermic and severe oligozoospermic).
We then calculated the overall frequency of the four FSHR
haplotypes in proven fathers and infertile men. As shown
in Table 3, no statistically signiﬁcant diﬀerence between the
groups was found (P>. 05 by χ2 test). To assess whether
the haplotypes inﬂuences FSH levels, we compared FSH
concentrations among genotypes. There were no signiﬁcant
diﬀerences in the FSH levels among the FSHR genotypes in
both the two groups of infertile and proven fathers (P>. 05,
ANOVA) (Table 2).
Test for deviation from Hardy-Weinberg proportions
has been performed, and the deviation from the Hardy-
Weinberg equilibrium (excess of homozygosity) takes placeJournal of Biomedicine and Biotechnology 3
Table 1: Genotypic frequencies and serum FSH concentrations (mean ± SD) in proven fathers and the two groups of infertile patients.
Proven fathers Nonobstructive azoospermic Severe oligozoospermic
Allele combination (n = 240) (n = 150) (n = 120)
Genotypic frequency










AA 13 (5.4) 3.4 ± 0.4 8 (5.3) 25.5 ± 2.8 6 (5) 11.9 ± 4,8
AG 49 (20.4) 3.4 ± 0.3 26 (17.3) 23.6 ± 1.4 27 (22.5) 13.9 ± 6.7
GG 178 (74.2) 3.5 ± 0.4 116 (77.3) 23.4 ± 2.4 87 (72.5) 14.3 ± 5.5
At codon 680
Asn-Asn 154 (64.2) 3.4 ± 0.3 94 (62.7) 22.3 ± 1.1 82 (68.3) 11.9 ± 4.5
Asn/Ser 49 (20.4) 3.3 ± 0.2 46 (30.7) 22.2 ± 1.2 13 (10.8) 14.1 ± 3.0
Ser-Ser 37 (15.4) 3.3 ± 0.4 10 (6.6) 23.0 ± 1.3 25 (20.8) 13.4 ± 3.5
Table 2: Allele combinations considering the FSHR polymorphisms at −29 and codon 680, genotype distribution, and serum FSH levels
(mean ± SE) in men with proven fathers and infertile (nonobstructive azoospermic and severe oligozoospermic). ∗The ﬁrst three groups (1,
2, and 3) were combined as one group in the Chi-square test.
Group Allele combination
(−29/680)
Proven fathers Nonobstructive azoospermic Severe Oligozoospermic
(n = 240) (n = 150) (n = 120)
Frequency
n (%) FSH(IU/I) Frequency
n (%) FSH(IU/I) Frequency
n (%) FSH(IU/I)
1∗ A-Asn/A-Asn 8 (3.33) 3.1 ± 0.4 5 (3.33) 23.1 ± 1.9 4 (3.33) 11.3 ± 5.7
2∗ A-Asn/A-Ser 2 (0.83) 2.9 ± 0.4 3 (2.00) 23.5 ± 1.9 1 (0.83) 12.5 ± 6.1
3∗ A-Ser/A-Ser 2 (0.83) 3.0 ± 0.5 1 (0.67) 24.0 ± 2.0 1 (0.83) 12.7 ± 6.4
4 A-Asn/G-Asn 31 (12.92) 3.4 ± 0.3 17 (11.33) 22.4 ± 1.2 21 (17.50) 12.3 ± 6.8
5 A-Asn/G-ser or
G-Asn/A-Ser 10 (4.17) 3.3 ± 0.3 8 (5.33) 22.8 ± 1.7 3 (2.50) 13.5 ± 7.2
6 A-Ser/G-Ser 7 (2.92) 3.4 ± 0.4 2 (1.33) 23.3 ± 1.3 6 (5.00) 13.6 ± 7.4
7 G-Asn/G-Asn 117
(48.75) 3.5 ± 0.4 73 (48.67) 21.5 ± 1.1 59 (49.17) 12.5 ± 5.5
8 G-Asn/G-Ser 36 (15.00) 3.3 ± 0.4 34 (22.67) 21.7 ± 1.3 8 (6.67) 13.7 ± 6.2
9 G-Ser/G-Ser 27 (11.25) 3.4 ± 0.4 7 (4.67) 22.4 ± 1.3 17 (14.17) 13.8 ± 6.0
almost for all investigated groups (except for SNP at
nucleotide position −29 for severe oligozoospermic group
and SNP 680 FSHR for nonobstructive azoospermic group).
4. Discussion
The impact of −29SNP, alone or in combination with exon
10SNPs, is less clear but does not seem to inﬂuence the
clinical parameters or plasma FSH concentrations both in
women and men [8, 10, 11]. Our data showed that the
genotype distribution of SNP −29 is similar both in proven
fathers and infertile men and does not inﬂuence serum FSH
levels when considered alone. This result was in agreement
withthosereportedintheprevioussimilarstudies[8,10,11],
but there are diﬀerences in the proportions of genotype
distribution between our study and others. The possible
ethnic diﬀerences might be responsible for this diﬀerence.
In women with normal ovarian function the polymor-
phismatcodon680oftheFSHRisanimportantdeterminant
of ovarian sensitivity to FSH [6, 8, 19, 25]. The SNP at
codon 680 was ﬁrstly conﬁrmed when Aittomaki et al. [26]
identiﬁed a loss-of-function mutation of FSH receptor in
ovarian dysgenesis due to Ala189Val. The SNP at position
6 8 0w a st h e nc o n ﬁ r m e da n dh a sb e e nw e l ls t u d i e db yP e r e z
Mayorgaetal.[6].Thedistributionwas29%fortheAsn/Asn,
45% for the Asn/Ser, and 26% for the Ser/Ser FSHR variant
[6]. In Japan, Sudo et al. [19] reported 522 ovulating women
who visited the university hospital. The proportions of
genotype Asn-Asn, Asn-Ser, and Ser-Ser were 41.0, 46.9, and
12.1%, respectively. In contrast to observations in women,
SNPs in exon 10 of the FSHR have no eﬀect on serum
levels of FSH and other clinical parameters in men with
either normal or impaired spermatogenesis [4, 7, 9]. Simoni
[2] evaluated Asn-Asn, Asn-Ser, and Ser-Ser (37.2, 45.4,
and 17.4%, resp.) in populations with proven fertility and
(32.0, 48.0, and 20.0%, resp.) infertility, and no signiﬁcant
diﬀerences were observed. In another study, Shimoda et al.
[15] reported that the proportions of Asn-Asn, Asn-Ser, and
Ser-Ser were 38.2, 47.3, and 13.1%, respectively, in subject4 Journal of Biomedicine and Biotechnology
Table 3: Allelic frequency in men with proven fathers (n = 240) and nonobstructive azoospermic (n = 150) and severe oligozoospermic
(n = 120) (P>. 05 by χ2 test).
Group Proven fathers n (%) Nonobstructive azoospermic n (%) Severe oligozoospermic n (%)
1 A-Asn 49 (10.2) 30 (10.0) 30 (12.5)
2 A-Ser 13 (2.7) 7 (2.3) 9 (3.8)
3 G-Asn 301 (62.7) 197 (65.7) 147 (61.2)
4 G-Ser 97 (20.2) 50 (16.7) 48 (20.0)
5∗ Undecided 20 (4.2) 16 (5.3) 6 (2.5)
∗Group 5 consists of alleles 1, 2, 3, and 4, which cannot be distinguished and are included in the statistical analysis as “dummy” variables.
with proven fertility and 49, 42, and 8% in infertile patients,
and there were no signiﬁcant diﬀerences between the two. In
our study, the genotype distribution of SNP at codon 680 is
diﬀerent between proven fathers and infertile men but does
not inﬂuence serum FSH levels when considered alone. This
result was in agreement with those reported by Ahda et al.
[8]. The diﬀerences in the genotype frequency might rep-
resent genetic factors contributing to phenotypic expression
of severe spermatogenetic impairment. The possible ethnic
diﬀerences might be responsible for this diﬀerence.
When considered in combinations with the SNP in
−29 and exon 10 (codon 307 and codon 680), there
are a few reports on aﬀected groups with diverse ethnic
backgrounds, and the results are not in agreement. A study
in German men investigated FSHR SNP genotypes (−29,
codon 307 and codon 680) alone or in combinations [8].
The authors concluded that while no FSHR haplotype was
associated with diﬀerent serum FSH levels, the A-Ala-Ser
and the G-Thr-Asn alleles might represent genetic factors
contributingtoseverespermatogeneticimpairment.Arecent
meta-analyses of FSHR SNP and male infertility revealed
that there is no any association with FSH serum levels or
sperm output [13]. A study in Italian men also investigated
the same three SNP genotypes and their combinations
[11]. The authors concluded that the genotypes had no
inﬂuenceonFSHconcentrationsinnormalorinfertilemales
and did not associate with spermatogenetic impairment.
However, very recently a study in Japanese men investigated
codon 307 and codon 680 genotypes and concluded that
heterozygous combination of Thr/Ala (codon 307) and
Ser/Asn (codon 680) was signiﬁcantly increased in infertile
patients compared with the controls but not Ser/Asn alone
[15]. In our study, the combination of the SNP at position
−29 and codon 680 gives rise to four haplotypes as these
alleles show a statistically similar distribution (except the
two allelic variants G-Asn/G-Ser G-Ser/G-Ser) in infertile
men compared to proven fathers and suggests that these
alleles might not represent a risk factor for male infertil-
ity.
In the test for deviation from Hardy-Weinberg propor-
tions, the deviation from the Hardy-Weinberg equilibrium
(excess of homozygosity) takes place almost for all inves-
tigated groups (except for SNP at nucleotide position −29
for severe oligozoospermic group and SNP 680 FSHR for
nonobstructive azoospermic group). This deviation is very
important with regard to high parental consanguinity in
populations like Turkey.
In conclusion, our data demonstrate that FSHR gene
polymorphisms seem not to have a direct inﬂuence on
spermatogenesis, but are diﬀerently distributed, identifying
an additional genetic factor possibly contributing to the
multigenic origin of male infertility. The discrepancies are
most likely due either to study subjects by chance or to study
diﬀerent genetic backgrounds in diﬀerent populations. In
populations like Turkey, high parental consanguinity could
bring out genetic factors or provide permissive background
for complex disorders. Additional studies on well-deﬁned
populations of infertile men will probably clarify these
aspects.
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